Final results of the dose-escalation part from the phase I trial evaluating IPH4102 in patients with advanced cutaneous T-cell lymphomas presented at the EORTC CLTF meeting
October 16, 2017Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that final results of the dose-escalation part of the ongoing Phase I study investigating IPH4102 in patients with...First half of 2017: delivering key clinical data and strengthening the pipeline
September 18, 2017Cash, cash equivalents and financial assets* for the Company amounted to €204.1m (million euros) as of June 30, 2017 Significant clinical progress within the period: Dose-escalation data of the...ICI conference 2017: new preclinical data further strengthen the rationale of IPH5401 and monalizumab for cancer treatments and in combination with anti-PD-1/PD-L1
September 11, 2017IPH5401, an anti-C5aR antibody, potentially reverses tumor immuno-suppressive microenvironment and overcomes tumor resistance; preclinical data suggest that combined C5aR and PD-1 blockade...Number of shares and voting rights of Innate Pharma as at August 4, 2017
August 8, 2017Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...Issuance by Innate Pharma of 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for rights in anti-C5aR
July 13, 2017The acquisition of the anti-C5aR, a first-in-class clinical-stage antibody, announced on June 2, 2017, is now finalized; The 3,343,748 new ordinary shares have been issued to Novo Nordisk A/S at a...Results of Annual General Meeting and changes to Innate Pharma’s governance and management team
June 26, 2017All proposed resolutions were voted according to management’s recommendations; Bpifrance Participations, represented by Maïlys Ferrere, and Pr. Jean-Charles Soria were appointed to the Supervisory...
